(Q36859988)

16 August 2017

1 reference

title

Pharmacologic and nonpharmacologic management of osteoporosis (English)

1 reference

16 August 2017

Jeffrey P Levine

1

1 reference

16 August 2017

1 January 2006

1 reference

16 August 2017

1 reference

16 August 2017

8

1 reference

16 August 2017

1

1 reference

16 August 2017

40-53

1 reference

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Improving compliance and persistence with bisphosphonate therapy for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Calcium plus vitamin D supplementation and the risk of fractures

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Estimates of optimal vitamin D status

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

The role of calcium in osteoporosis drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

RETRACTED: Risedronate therapy for prevention of hip fracture after stroke in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Drug combination strategies for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Compliance with osteoporosis medications

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980064-5

7 January 2021

10.1016/S1098-3597(06)80064-5

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17591575